Sökning: onr:"swepub:oai:DiVA.org:uu-90342" >
Immunization of col...
-
Ullenhag, GustavUppsala universitet,Enheten för onkologi
(författare)
Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response
- Artikel/kapitelEngelska2003
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-90342
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-90342URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1937667URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PURPOSE: Colorectal carcinoma cells express the tumor-associated antigen epithelial cellular adhesion molecule (Ep-CAM)/KSA. Passive immunotherapy with monoclonal antibodies using this antigen has shown promising results. Ep-CAM might also be a target for active specific immunotherapy. Expression of the tumor antigen in a viral vector may facilitate appropriate antigen presentation. The feasibility of an Ep-CAM/KSA-specific therapeutic vaccination was investigated in cancer patients.EXPERIMENTAL DESIGN: The full-length Ep-CAM gene was inserted into the avipox virus ALVAC (ALVAC-KSA). Twelve radically operated colorectal carcinoma patients without evidence of remaining macroscopic disease (stages I, II, and III) entered the study. The first 6 patients were immunized with three injections of ALVAC-KSA (10(7.09) CCID(50) per immunization) alone in weeks 0, 3, and 6. The subsequent 6 patients received the same schedule of ALVAC-KSA together with the adjuvant cytokine granulocyte macrophage colony-stimulating factor (GM-CSF; 75 micro g/day for 4 consecutive days).RESULTS: The adverse reactions to the vaccinations were mild except for local skin reactions. In the ALVAC-KSA group a weak T-cell response was induced in 2 of 6 patients. In the ALVAC-KSA/GM-CSF group a marked IFN-gamma response (enzyme-linked immunospot) was induced in 5 of 6 patients. The T-cell response appeared late, 1 month after the last immunization, with a peak at 4-5 months after immunization. No IgG antibodies against Ep-CAM were detected. Before vaccination the majority of patients had a type 1 T-cell response (IFN-gamma) against the vector, which was noted in healthy donors as well. All of the patients developed high titers of IgG antibodies against the vector, and the T-cell response was vigorously boosted.CONCLUSIONS: ALVAC-KSA, in combination with low dose local administration of GM-CSF may induce a strong, IFN-gamma T-cell response (type 1). ALVAC-KSA seems to be an interesting candidate as a cancer vaccine for future clinical development.
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Frödin, Jan-ErikKarolinska Institutet
(författare)
-
Mosolits, Szilvia
(författare)
-
Kiaii, ShahryarKarolinska Institutet
(författare)
-
Hassan, MoustaphaKarolinska Institutet
(författare)
-
Bonnet, Marie-Claude
(författare)
-
Moingeon, Philippe
(författare)
-
Mellstedt, HåkanKarolinska Institutet
(författare)
-
Rabbani, HodjatallahKarolinska Institutet
(författare)
-
Uppsala universitetEnheten för onkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Clinical Cancer Research9:7, s. 2447-24561078-04321557-3265
Internetlänk
Hitta via bibliotek
Till lärosätets databas